Thomas Advanced Medical — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Thomas Advanced Medical is a private, early-stage biotech firm operating in the cell and gene therapy sector, headquartered in Nashville, Tennessee. Founded in 2018, the company is led by a physician-scientist team and is currently in the pre-clinical or early clinical research phase, investigating stem cell-based regenerative therapies. It appears to be a pre-revenue entity dedicated to research and development, with a business model centered on developing therapeutics. The company's public-facing communication emphasizes scientific rigor and appropriate patient consultation regarding the experimental nature of its work.

Regenerative Medicine

Technology Platform

Stem cell-based regenerative therapy platform focused on biological therapeutics, emphasizing rigorous scientific studies and clinical research.

Opportunities

The global regenerative medicine market offers significant growth potential, particularly for stem cell therapies targeting chronic degenerative diseases with high unmet need.

Nashville's position as a major healthcare hub provides access to clinical expertise and potential collaborative networks.

Risk Factors

The company faces high scientific risk due to the unproven nature of stem cell therapies for many conditions, significant regulatory hurdles for cell-based products, and critical financial risk as a pre-revenue entity dependent on external funding.

Competitive Landscape

Thomas Advanced Medical operates in a highly competitive field dominated by large pharmaceutical companies, well-funded public biotechs, and leading academic institutions, all investing heavily in cell and gene therapy. Its success depends on differentiating its scientific approach and securing the capital needed to compete.

More companies in Cell & Gene Therapy →More companies in United States →